Plasmid-based therapeutic vaccination platform : a proof of concept in melanoma

Keywords

DNA vaccine
Immunotherapy
Immuno-oncology

Technology Market:

Therapeutic cancer vaccine

Immuno-oncology has provided breakthrough in cancer therapy. Immunotherapy drugs aim at modifying the tumor environment by reducing immunosuppression to favour immune recognition of tumor antigens. However, not all the patients respond to these treatments.
Today, there is thus a crucial need for additional strategies able to increase the number of patients who can benefit from immunotherapy. This could be obtained by training their immune system to better recognize the cancer cells using therapeutic cancer vaccines.

The ADDB Lab Expertise

Drug delivery
Design, cloning and production of DNA vaccines
DNA electroporation
Preclinical evaluation of cancer vaccines with in-depth characterization of immune responses

The UCLouvain collaboration offer

We have developed a DNA-based platform technology for therapeutic cancer vaccine design and provided proof of concept in a range of mice tumors. The pTOP technology relies on the combined delivery of:

A carrier sequence (e.i. vesicular stomatitis virus glycoprotein)displaying adjuvant properties
CD8 epitopes to generate CTL responses
CD4 helper epitopes

We aim to partner with academia and industries to develop therapeutic cancer vaccines for use in Human and to identify winning “pTOP-drug“ combinations with the potential to cure more patients thanks to synergistic action modes.

Preferred partnership

Collaboration with pharmaceutical companies that develop immune checkpoint inhibitors or other immunotherapy drugs.

Interested to benefit from these services?

Please contact :

François LOUESSE
Technology Transfer Advisor
010 47 25 49
francois.louesse@uclouvain.be
www.ltto.com